UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 2930, 2026

Quince Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware	001-38890	90-1024039
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
(State or Other Jurisdictionof Incorporation)	(CommissionFile Number)	(IRS EmployerIdentification No.)


611 Gateway Boulevard Suite 273
South San Francisco, California		94080
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (415) 910-5717

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	QNCX	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item. 85.0102. ~~Other~~Departure ~~Events~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 2930, 2026, ~~Quince~~each ~~Therapeutics~~of Rajiv Patni, ~~Inc.~~Luca ~~issued~~Benatti, aMargi ~~press~~McLoughlin, ~~release~~Una ~~announcing~~Ryan, ~~results~~and ~~from~~June ~~Pivotal~~Bray ~~Phase~~tendered 3his ~~NEAT~~or ~~Clinical~~her ~~Trial~~resignation ofas ~~eDSP~~a inmember ~~Ataxia-Telangiectasia.~~of Athe ~~copy~~Board of ~~this~~Directors ~~press~~of ~~release~~Quince isTherapeutics, ~~attached~~Inc. ~~hereto~~(the “Company”), effective as ~~Exhibit~~of 99January 30, 2026.1 Such resignations were not the result of any disagreement between such director and isthe ~~incorporated~~Company byon ~~reference~~any ~~herein~~matter relating to the Company’s operations, policies, or practices.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release issued by Quince Therapeutics, Inc. dated January 29, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

QUINCE THERAPEUTICS, INC.

Date: January 29, 2026

Date: February 2, 2026

/s/ Dirk Thye

Chief Executive Officer and Chief Medical Officer

Filing Compare · Quince Therapeutics, Inc.